Barclays downgraded shares of Biohaven Pharmaceutical (NYSE:BHVN) from an overweight rating to an equal weight rating in a research note released on Thursday, Marketbeat reports. The brokerage currently has $25.00 price target on the stock, down from their prior price target of $30.00.
Several other equities research analysts have also commented on BHVN. Canaccord Genuity reaffirmed a buy rating and issued a $39.00 price target (up from $30.00) on shares of Biohaven Pharmaceutical in a report on Thursday, February 22nd. Piper Jaffray reaffirmed a buy rating on shares of Biohaven Pharmaceutical in a report on Monday, March 26th. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a hold rating to a buy rating and set a $33.00 price target on the stock in a report on Friday, March 9th. Finally, Needham & Company LLC reaffirmed a buy rating on shares of Biohaven Pharmaceutical in a report on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $37.14.
NYSE:BHVN traded down $0.82 during mid-day trading on Thursday, hitting $23.68. The company’s stock had a trading volume of 356,422 shares, compared to its average volume of 767,385. Biohaven Pharmaceutical has a 1 year low of $16.50 and a 1 year high of $39.51. The firm has a market cap of $905.84 and a price-to-earnings ratio of -4.81.
Several hedge funds have recently bought and sold shares of the company. VHCP Management II LLC boosted its stake in shares of Biohaven Pharmaceutical by 3.3% during the 4th quarter. VHCP Management II LLC now owns 1,718,605 shares of the company’s stock worth $46,368,000 after acquiring an additional 54,305 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Biohaven Pharmaceutical by 84.9% during the 4th quarter. Alliancebernstein L.P. now owns 1,597,756 shares of the company’s stock worth $43,107,000 after acquiring an additional 733,526 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Biohaven Pharmaceutical by 1.1% during the 4th quarter. BlackRock Inc. now owns 1,154,207 shares of the company’s stock worth $31,139,000 after acquiring an additional 12,505 shares in the last quarter. Eagle Asset Management Inc. raised its position in shares of Biohaven Pharmaceutical by 20.4% during the 4th quarter. Eagle Asset Management Inc. now owns 1,104,999 shares of the company’s stock worth $30,207,000 after purchasing an additional 187,243 shares during the last quarter. Finally, Carillon Tower Advisers Inc. acquired a new position in shares of Biohaven Pharmaceutical during the 4th quarter worth about $18,627,000. 61.84% of the stock is currently owned by institutional investors and hedge funds.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.